8-K current report · filed Nov 5, 2026

TANDEM DIABETES CARE INC (TNDM) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1TNDM overview

Short answer

TANDEM DIABETES CARE INC (TNDM) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.

TANDEM DIABETES CARE INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 sales $283.7M, up 14%, with international growth 26% versus U.S. growth 9%
  • Gross margin 57%, up 270 basis points, while operating loss narrowed to $2.4M from $22.9M
  • Adjusted EBITDA $18.0M, or 6% margin, versus $2.8M and 1% margin, signaling substantial operating leverage
  • Pharmacy channel reached 15% of U.S. sales, with formulary coverage expanded to approximately 50% of U.S. lives
  • 2026 guidance reaffirmed: sales $1.065B-$1.085B and adjusted EBITDA margin 5%-6%

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other TANDEM DIABETES CARE INC 8-K filings

Get the next TNDM 8-K as it lands

Follow TNDM for push alerts, or ask the research agent what this filing means.